

Att. Docket No. REG 670A-US
USSN 09/868,677 filed October 1, 2001
Amendment And Response To December 7, 2001
Notification Of Missing Requirements

which corresponds to nucleotides 1-675 of Figure 15A-Figure 15B (SEQ ID NO: 11), followed by a bridging sequence consisting of the amino acids Gly-Pro-Gly (nucleotides 676-684 of Figure 15B [SEQ ID NO: 11]), followed by a second copy of the ectodomain of Ephrin-B2 (corresponding to nucleotides 685-1270 of Figure 15B-Figure 15D [SEQ ID NO: 11]), except that in this copy the signal sequence has been removed. This second copy is followed by a second Gly-Pro-Gly amino acid bridge (nucleotides 1270-1278 of Figure 15D [SEQ ID NO: 11]), followed by the coding sequence for the Fc portion of human IgG1 (nucleotides 1279-1977 of Figure 15D-Figure 15E [SEQ ID NO: 11]). This molecule was subcloned into the HindIII and NotI polylinker sites in the expression vector pRG763 and was designated pRG763-m(Ephrin-B2)2-Fc. As with the angiopoietin nucleic acid molecules described *supra*, the bridging sequences were introduced to provide convenient restriction sites and to give flexibility to the junctions between the domains.

REMARKS


This amendment is being made merely to insert the sequence identifiers. Applicants submit herewith as Exhibit 1: a copy of the December 7, 2001 Notification; Exhibit 2: copy of Transmittal of Sequence Listing submitted concurrently to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202; Exhibit 3: Marked-Up Versions of amended pages 4, 7, 26, 27, 29, 31, 32, 37, 38, 39, 41, 42, and 44.

Applicants have directed the subject Sequence Listings submitted with the Transmittal of Sequence Listing be added to the specification.

Att. Docket No. REG 670A-US
USSN 09/868,677 filed October 1, 2001
Amendment And Response To December 7, 2001
Notification Of Missing Requirements

No fee is deemed necessary in connection with the filing of this Response.
However, if any fee is required, authorization is hereby given to charge the amount
of any such fee to Deposit Account No. 18-0650.

Respectfully submitted,



Linda O. Palladino
Reg. No. 45,636
Patent Agent for Applicants
Gail M. Kempler
Reg. No. 32,143
Joseph M. Sorrentino
Reg. No. 32,598
Laura J. Fischer
Reg. No. P-50,420
Attorneys for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400